“Elotuzumab: The First Available Immunotherapeutic Arrow Against Relapsed-Refractory Multiple Myeloma”. European Journal of Oncology and Environmental Health, vol. 22, no. 2, Nov. 2017, pp. 65-70, https://mattioli1885journals.com/index.php/EJOEH/article/view/6857.